Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer

• Published in: European journal of drug metabolism and pharmacokinetics Vol. 47; no. 5; pp. 711 - 723
• Main Authors: Liao, Mingxiang, Zhou, Jie, Wride, Kenton, Lepley, Denise, Cameron, Terri, Sale, Mark, Xiao, Jim
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.09.2022
• Subjects: Biomedical and Life Sciences; Biomedicine; Human Physiology; ISRCTN; ISRCTN23201971; Medical Biochemistry; NCT; NCT01283945; NCT02053636; NCT02109016; NCT02202746; Original; Original Research Article; Pharmaceutical Sciences/Technology; Pharmacology/Toxicology; Pharmacy
• ISSN: 0378-7966; 2107-0180; 2107-0180
• DOI: 10.1007/s13318-022-00773-w

Background Lucitanib is an oral, potent, selective inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1‒3, fibroblast growth factor receptors 1‒3, and platelet-derived growth factor receptors alpha/beta. Objective We aimed to develop a population pharmacokinetics (PopPK) model for lucitanib in patients with advanced cancers. Methods PopPK analyses were based on intensive and sparse oral pharmacokinetic data from 5 phase 1/2 clinical studies of lucitanib in a total of 403 patients with advanced cancers. Lucitanib was administered at 5‒30 mg daily doses as 1 of 2 immediate-release oral formulations: a film-coated tablet or a hard gelatin capsule. Results Lucitanib pharmacokinetics were best described by a 2-compartment model with zero-order release into the dosing compartment, followed by first-order absorption and first-order elimination. Large between-subject pharmacokinetic variability was partially explained by body weight. No effects of demographics or tumor type on lucitanib pharmacokinetics were observed. The model suggested that the formulation impacted release duration (tablet, 0.243 h; capsule, 0.814 h), but the effect was not considered clinically meaningful. No statistically significant effects were detected for concomitant cytochrome P450 (CYP) 3A4 inhibitors or inducers, CYP2C8 or P-glycoprotein inhibitors, serum albumin, mild/moderate renal impairment, or mild hepatic impairment. Concomitant proton pump inhibitors had no clinically significant effect on lucitanib absorption. Conclusions The PopPK model adequately described lucitanib pharmacokinetics. High between-subject pharmacokinetic variability supports a safety-based dose-titration strategy currently being used in an ongoing clinical study of lucitanib to optimize drug exposure and clinical benefit. Trial Registration ClinicalTrials.gov Identifier: NCT01283945, NCT02053636, ISRCTN23201971, NCT02202746, NCT02109016.